Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
BioNexus Gene Lab Corp Common stock (BGLC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/08/2026: BGLC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -90.35% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/08/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.98M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.91 | 52 Weeks Range 2.01 - 6.50 | Updated Date 06/29/2025 |
52 Weeks Range 2.01 - 6.50 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.19 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -22.86% | Operating Margin (TTM) -27.47% |
Management Effectiveness
Return on Assets (TTM) -14.05% | Return on Equity (TTM) -24.75% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1581259 | Price to Sales(TTM) 0.54 |
Enterprise Value 1581259 | Price to Sales(TTM) 0.54 | ||
Enterprise Value to Revenue 0.17 | Enterprise Value to EBITDA 629.53 | Shares Outstanding 1796600 | Shares Floating 1240011 |
Shares Outstanding 1796600 | Shares Floating 1240011 | ||
Percent Insiders 51.11 | Percent Institutions 0.88 |
Upturn AI SWOT
BioNexus Gene Lab Corp Common stock
Company Overview
History and Background
BioNexus Gene Lab Corp. (BGLC) is a biotechnology company focused on developing and commercializing diagnostic and therapeutic solutions. While specific founding year and detailed historical milestones are not readily available for public common stock analysis, the company operates within the rapidly evolving field of genetic and molecular diagnostics. Its evolution is likely tied to advancements in gene sequencing, personalized medicine, and the growing demand for early disease detection and targeted therapies.
Core Business Areas
- Diagnostic Solutions: Development and offering of diagnostic tests, likely leveraging molecular and genetic technologies for disease identification and monitoring.
- Therapeutic Development: Research and development of novel therapeutic approaches, potentially based on gene-based or cellular therapies.
Leadership and Structure
Information regarding BioNexus Gene Lab Corp.'s specific leadership team and organizational structure is not publicly detailed in a way that can be easily summarized for common stock analysis. Such details are typically found in company filings or investor relations sections of their official website.
Top Products and Market Share
Key Offerings
- Product Name 1: Specific diagnostic test kits for infectious diseases or genetic disorders. Market share data, user numbers, and revenue from specific products are not publicly disclosed. Competitors would include large diagnostic companies and specialized biotech firms.
- Product Name 2: Gene sequencing services or bioinformatics platforms. Market share data, user numbers, and revenue from specific products are not publicly disclosed. Competitors would include companies offering similar sequencing technologies and data analysis services.
Market Dynamics
Industry Overview
The biotechnology and diagnostics industry is characterized by rapid innovation, high R&D costs, stringent regulatory processes, and significant growth potential driven by an aging global population, increasing healthcare spending, and advancements in scientific understanding.
Positioning
BioNexus Gene Lab Corp. is positioned as a player in the specialized segment of molecular and genetic diagnostics and therapeutics. Its competitive advantages, if any, would likely stem from proprietary technology, specific product efficacy, or strategic partnerships. However, without detailed public disclosures, assessing its precise market position and advantages is challenging.
Total Addressable Market (TAM)
The TAM for genetic diagnostics and personalized medicine is substantial and growing, estimated in the hundreds of billions of dollars globally. BioNexus Gene Lab Corp.'s positioning within this TAM is likely niche, focusing on specific disease areas or technologies. Its success will depend on its ability to capture market share within these niches.
Upturn SWOT Analysis
Strengths
- Focus on a high-growth sector (biotechnology, diagnostics).
- Potential for innovative proprietary technologies.
- Adaptability to emerging scientific advancements.
Weaknesses
- Limited public information on products, financials, and leadership.
- Potential for high R&D costs and long development cycles.
- Dependence on regulatory approvals.
- Likely early-stage company with unproven commercial success.
Opportunities
- Increasing demand for personalized medicine and early disease detection.
- Advancements in gene editing and genomic technologies.
- Potential for strategic partnerships and collaborations.
- Expansion into emerging markets.
Threats
- Intense competition from established biotech and diagnostic companies.
- Rapid technological obsolescence.
- Stringent and evolving regulatory landscape.
- Funding challenges for early-stage biotech companies.
- Patent expirations and generic competition for successful products.
Competitors and Market Share
Key Competitors
- Quest Diagnostics Incorporated (DGX)
- Labcorp Holdings Inc. (LH)
- Thermo Fisher Scientific Inc. (TMO)
- Roche Holding AG (RHHBY)
- Illumina, Inc. (ILMN)
Competitive Landscape
BioNexus Gene Lab Corp. operates in a highly competitive landscape dominated by larger, well-established players with extensive R&D budgets, established distribution channels, and strong brand recognition. Its competitive advantage would need to be built on highly specialized, innovative products or disruptive technologies that address unmet needs.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends are not publicly discernible due to a lack of detailed financial reporting for common stock analysis.
Future Projections: Specific analyst projections for BioNexus Gene Lab Corp.'s future growth are not readily available.
Recent Initiatives: Information on recent strategic initiatives is not publicly detailed.
Summary
BioNexus Gene Lab Corp. is a speculative entity in the biotechnology sector, focusing on diagnostics and therapeutics. The company operates in a dynamic and high-potential market but faces significant challenges due to a lack of public financial transparency, intense competition from established giants, and the inherent risks of early-stage biotech development. Its success hinges on its ability to innovate and secure funding, while its current lack of detailed public information makes a comprehensive assessment difficult.
Similar Stocks
Sources and Disclaimers
Data Sources:
- General industry knowledge of the biotechnology and diagnostics market.
- Publicly available information is limited for BioNexus Gene Lab Corp. Common stock analysis.
Disclaimers:
This analysis is based on limited publicly available information and general industry trends. BioNexus Gene Lab Corp. Common stock is likely a highly speculative investment. Investors are strongly advised to conduct their own thorough due diligence and consult with a qualified financial advisor before making any investment decisions. Information regarding specific products, market share, and financials is not readily accessible, limiting the depth of this analysis.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BioNexus Gene Lab Corp Common stock
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-09-16 | CEO, President, Acting CFO, Secretary & Director Mr. Su-Leng Tan | ||
Sector Basic Materials | Industry Specialty Chemicals | Full time employees 30 | Website https://www.bionexusgenelab.com |
Full time employees 30 | Website https://www.bionexusgenelab.com | ||
BioNexus Gene Lab Corp., through its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; and Investment Holding. It offers various chemical raw material products, including polyester resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; polyester resin 9509, a general-purpose material used in the production of marine boats and water slides; and polyester resin 2802, which is used as a component in the pultrusion process. The company's products are used in producing various finished goods, such as handrails, bench tops, and automotive and aero parts; paneling for hospital, laboratory, and industrial clean rooms; and covers for various instruments used in manufacturing. It also develops and provides non-invasive liquid biopsy tests for the early detection of biomarkers. BioNexus Gene Lab Corp. was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.